Former FDA chiefs slam Trump admin over staff exodus; AstraZeneca inks AI deal

Three former FDA commissioners publicly criticized the Trump administration and the former FDA leadership for overseeing a large-scale staff departure, calling the DOGE-related cuts a 'disaster.' Separately, AstraZeneca announced an AI partnership, but the core intelligence item is the political fallout over FDA workforce attrition, which signals potential regulatory disruption. The criticism is rhetorical, but the underlying staff exodus could affect drug approval timelines and public health readiness.